Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors.
We investigated the effect of protein kinase and phosphatase inhibitors on the growth of six human prostatic cancer cell lines: DU145, PC3, ND1, LNCaP, ALVA31 and JCA1. We studied okadaic acid and sodium orthovanadate as serine/threonine and tyrosine protein phosphatase inhibitors, respectively, and staurosporin and genistein as a serine/threonine and tyrosine protein kinase inhibitors, respectively. All inhibitors examined exhibited a dose-dependent growth inhibitory effect on prostatic cancer cell lines. Our data indicate that prostatic cancer cell lines express unique biochemical properties since the degree of growth inhibition varied greatly and was dependent on the specific cell line and inhibitor studied. In addition, we found that surface expression of endoglin (CD105) changed by treatment with all inhibitors in most of the cell lines. These data also indicate that endoglin appears to be involved both in protein phosphatase and kinase mediated phosphoprotein turnover.
Rokhlin
O W
OW
Department of Pathology, University of Iowa, Iowa City 52242, USA.
Cohen
M B
MB
D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use; D015703:Antigens, CD; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D015815:Cell Adhesion Molecules / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D000071063:Endoglin; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004988:Ethers, Cyclic / Q000494:pharmacology / Q000627:therapeutic use; D019833:Genistein; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D019319:Okadaic Acid; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D010766:Phosphorylation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011956:Receptors, Cell Surface; D019311:Staurosporine; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology; D014638:Vanadates / Q000494:pharmacology / Q000627:therapeutic use; D019010:Vascular Cell Adhesion Molecule-1 / Q000096:biosynthesis
D000470:Alkaloids; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; C064206:ENG protein, human; D000071063:Endoglin; D004791:Enzyme Inhibitors; D004988:Ethers, Cyclic; D018960:Hyaluronan Receptors; D007529:Isoflavones; D011956:Receptors, Cell Surface; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D019319:Okadaic Acid; D014638:Vanadates; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D010749:Phosphoprotein Phosphatases; D017027:Protein Tyrosine Phosphatases; D019311:Staurosporine